Cargando…

Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+)

Detalles Bibliográficos
Autores principales:	Leite, Luiz Arthur Calheiros, Kerbauy, Daniela Márcia Bahia, Kimura, Elisa, Yamamoto, Mihoko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Hematologia e Hemoterapia 2012
Materias:	Letters to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459618/ https://www.ncbi.nlm.nih.gov/pubmed/23049389 http://dx.doi.org/10.5581/1516-8484.20120019

Ejemplares similares

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

The Assessment of CD56 and CD117 Expressions at the Time of the Diagnosis in Multiple Myeloma Patients
por: Ceran, Funda, et al.
Publicado: (2017)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma
por: Zheng, Dong, et al.
Publicado: (2022)

Activation of Blood CD3(+)CD56(+)CD8(+) T Cells during Pregnancy and Multiple Sclerosis
por: de Andrés, Clara, et al.
Publicado: (2017)

Key Role of the CD56(low)CD16(low) Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells
por: Vulpis, Elisabetta, et al.
Publicado: (2018)

PB1951: INVESTIGATION OF THE RELATIONSHIP BETWEEN CD56 AND CD117 EXPRESSIONS AND CLINICAL AND LABORATORY FINDINGS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS
por: Akkurd, D. M., et al.
Publicado: (2022)

NK cells CD56(bright) and CD56(dim) subset cytokine loss and exhaustion is associated with impaired survival in myeloma
por: Seymour, Frances, et al.
Publicado: (2022)

The frequencies of peripheral blood CD5(+)CD19(+) B cells, CD3(−)CD16(+)CD56(+) NK, and CD3(+)CD56(+) NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder
por: Khani, Leila, et al.
Publicado: (2022)

Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study
por: Li, Liping, et al.
Publicado: (2022)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

CD4(+)CD25(+) cells in multiple myeloma related renal impairment
por: Huang, Hongdong, et al.
Publicado: (2015)

The phenotype of CD3–CD56(bright) and CD3–CD56(dim) natural killer cells in systemic lupus erythematosus patients and its relation to disease activity
por: Soelistyoningsih, Dwi, et al.
Publicado: (2022)

Alterations in the CD56(−) and CD56(+) T Cell Subsets during COVID-19
por: Vavilova, Julia D., et al.
Publicado: (2023)

Numerical status of CD4(+)CD25(+)FoxP3(+) and CD8(+)CD28(-) regulatory T cells in multiple sclerosis
por: Kouchaki, Ebrahim, et al.
Publicado: (2014)

CD56(dim)CD16(high) and CD56(bright)CD16(−) cell percentages associated with maximum knee extensor strength and incidence of death in elderly
por: Senpuku, Hidenobu, et al.
Publicado: (2016)

Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation
por: Geng, Chuanying, et al.
Publicado: (2022)

Evidence Implicating the Ras Pathway in Multiple CD28 Costimulatory Functions in CD4(+) T Cells
por: Janardhan, Sujit V., et al.
Publicado: (2011)

Increased Percentage of CD8(+)CD28(−) Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis
por: Houston, Timothy W., et al.
Publicado: (2022)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms
por: Thiago, Leandro S., et al.
Publicado: (2013)

t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
por: Narita, T, et al.
Publicado: (2015)

CD28(−) and CD28(low)CD8(+) Regulatory T Cells: Of Mice and Men
por: Vuddamalay, Yirajen, et al.
Publicado: (2017)

Sustained CD28 Expression Delays Multiple Features of Replicative Senescence in Human CD8 T Lymphocytes
por: Parish, Stanley T., et al.
Publicado: (2010)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

NCAM (CD56) Expression in keratin-producing odontogenic cysts: aberrant expression in KCOT
por: Vera-Sirera, Beatriz, et al.
Publicado: (2015)

Primary Esophageal Melanoma with Aberrant CD56 Expression: A Potential Diagnostic Pitfall
por: Katerji, Hani, et al.
Publicado: (2017)

Immunohistochemical evaluation of CD20 expression in patients with multiple myeloma
por: Yavasoglu, Irfan, et al.
Publicado: (2015)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
por: Lewinsky, Hadas, et al.
Publicado: (2021)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma
por: Yoshida, Takashi, et al.
Publicado: (2018)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

CD19( (+)) CD56( (–)) myeloma arising in a patient who failed two courses of immunosupressive therapy for aplastic anaemia
por: Murray, Nigel P, et al.
Publicado: (2017)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

Local CD4+, CD8+ and CD56+ T-lymphocite Reaction on Primary Lung Cancer
por: Jusufovic, Edin, et al.
Publicado: (2011)

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
por: Bartosińska, Joanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g6agmf3as6f3ljr9j96jqfvfop